Novo Nordisk | Pasivo Circulante



Current Liabilities Cambio Fecha
ANI Pharmaceuticals USD 193.68M 3.75M 2024-12
Aurora Cannabis CAD 149.81M 40.71M 2024-12
Bausch Health Companies USD 4.51B 137M 2024-09
Bristol-Myers Squibb USD 23.77B 1.14B 2024-12
Canopy Growth CAD 97.02M 184.27M 2024-12
Corcept Therapeutics USD 140.77M 14.56M 2024-12
Drreddys Laboratories INR 131.95B 2.65B 2024-12
Eli Lilly USD 28.38B 3.7B 2024-12
GlaxoSmithKline GBP 21.7B 238M 2024-12
Merck USD 28.42B 1.17B 2024-12
Novartis USD 28.69B 560M 2024-12
Novo Nordisk 208.36B 20.45B 2024-09
Novo Nordisk DKK 208.36B 20.45B 2024-09
Pacira USD 309.92M 3.52M 2024-12
Perrigo USD 1.04B 406.3M 2024-12
Prestige Brands USD 102.54M 4.36M 2024-12
Sanofi 30.03B 5.82B 2024-06
Supernus Pharmaceuticals USD 292.4M 889K 2024-12
Zoetis USD 3.41B 1.71B 2024-12



Novo Nordisk Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.